To date there are few studies regarding the pathophysiology of lamin A DE11, hence the spliceswitching method here may offer an inducible model to further study this disease. Given that the lamin A DE11 product, like progerin, is presumably permanently farnesylated and that restrictive dermopathy demonstrates similar nuclear abnormalities to HGPS, it is possible that lamin A DE11 will have similar downstream effects to those caused by progerin. Lamin A DE11 is probably as deleterious as, if not more so, progerin in HGPS, considering the extreme phenotype of restrictive dermopathy. Indeed, the fact that accumulation of progerin and lamin A DE11 can both cause restrictive dermopathy suggests that HGPS and restrictive dermopathy belong to the same clinical spectrum of diseases caused by farnesylated prelamin A. Therefore, although there is a mixture of cryptic splicing activation and exon 11 skipping in the AO treated myogenic cells in the present study, it is our belief that the induced products, progerin and lamin A DE11, exert similar effects in cells to cause accelerated ageing. Consistent with this hypothesis, similarly mis-shapen myonuclei were found in myogenic cells treated with the PMOs that induced progerin alone and both progerin and lamin A DE11. Premature ageing can be induced in fibroblasts and human midbrain dopamine neurons derived from induced pluripotent stem cells by transfection with a synthetic RNA that encodes progerin tagged with GFP. Enhanced expression of progerin was only achieved after 3 and 5 repeats of daily transfection in iPSfibroblasts and iPS-neurons respectively. In contrast, 36 hours after transfection. It will be interesting to evaluate the consequences of progerin expression arising from PMO induced splice switching in iPS-fibroblasts and iPS-neurons. In conclusion, we have shown that AOs targeting the putative ESEs\/ESSs within exon 11 of LMNA or the donor site, can be used to redirect splicing in human myogenic cells, and lead to the production of two distinctive, yet functionally similar, farnesylated prelamin A isoforms. The PMO chemistry was found to be more effective than the 2OMe chemistry in terms of specificity and progerin production. The PMOs increased production of progerin and induced the nuclear changes associated with premature ageing, similar to those that occur in HGPS. Atmospheric concentrations of carbon dioxide, methane and nitrous oxide have increased considerably since the industrial revolution, and are still increasing annually by about 0.5%, 1.1% and 0.3%, respectively. Worldwide concerns about the increased greenhouse gases concentrations in the atmosphere and its effects on our future environment require a better understanding of the cause of these emissions. Agricultural lands occupy 37% of the earth’s land surface; about 13.5% of global anthropogenic GHG was emitted from agricultural production.<\/p>\n","protected":false},"excerpt":{"rendered":"
To date there are few studies regarding the pathophysiology of lamin A DE11, hence the spliceswitching method here may offer an inducible model to further study this disease. Given that the lamin A DE11 product, like progerin, is presumably permanently farnesylated and that restrictive dermopathy demonstrates similar nuclear abnormalities to HGPS, it is possible that … Continue reading “The splice switching PMOs in this study induced more readily detectable amounts of progerin”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1536"}],"collection":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=1536"}],"version-history":[{"count":1,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1536\/revisions"}],"predecessor-version":[{"id":1537,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1536\/revisions\/1537"}],"wp:attachment":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=1536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=1536"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=1536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}